Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

19 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Asimia Articles

FDA news briefs: Biogen Idec's rFIXFc BLA accepted; 2nd CRL for Xarelto sNDA; negative vote on Depomed's Sefelsa and Hisamitsu's paroxetine mesylate

5 March 2013

UPDATE: Sanofi falls 6% on news of EU generic Plavix, but it may not be substitutable

19 May 2008

Sanofi falls 5% on news of EU generic Plavix, but it may not be substitutable

19 May 2008

Noven to buy JDS Pharma in $125M deal

26 July 2007

US FDA to update black box warnings for young adults taking antidepressants

14 May 2007

Alpharma and Synthon to co-promote Pexeva

24 January 2005

GlaxoSmithKline facing increased generic competition in the USA

11 August 2003

GSK's Wellbutrin XL on track for approval

7 July 2003

Synthon challenges SB's Paxil patent?

10 January 2000

Showing 1-9 of 9 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Negative US patent ruling for Novo Nordisk on Prandin
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Daiichi Sankyo files for Japanese approval of Prasugrel
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Negative US patent ruling for Novo Nordisk on Prandin
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Daiichi Sankyo files for Japanese approval of Prasugrel

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS